Wang D Y, Rubens R D, Clark G M, Moore J W, Bulbrook R D
Imperial Cancer Research Fund, London, United Kingdom.
Breast Cancer Res Treat. 1988 Apr;11(1):67-70. doi: 10.1007/BF01807560.
Serum sex hormone binding globulin (SHBG) was measured in 21 pre and 39 postmenopausal women with advanced breast cancer before treatment and 1, 3, 6, 9 and 12 months after ovarian irradiation or during continuous administration of tamoxifen at a dose of 10 mg twice daily, respectively; some patients received additional prednisolone at a dose of 5 mg twice a day. Ovarian irradiation was associated with a 25% reduction in serum SHBG levels 3 to 6 months after treatment whilst patients on tamoxifen experienced a rise of about 80% in serum SHBG levels after 1 to 3 months. In postmenopausal women prednisolone markedly dampened the effect of tamoxifen, reducing a 80% rise to about 20%. There was no relationship between SHBG levels and response to treatment.
对21名绝经前和39名绝经后晚期乳腺癌女性患者在治疗前以及分别在卵巢放疗后1、3、6、9和12个月或每天两次服用10毫克他莫昔芬期间测定血清性激素结合球蛋白(SHBG)水平;部分患者额外每天两次服用5毫克泼尼松龙。卵巢放疗后3至6个月血清SHBG水平降低25%,而服用他莫昔芬的患者在1至3个月后血清SHBG水平升高约80%。在绝经后女性中,泼尼松龙显著减弱了他莫昔芬的作用,将80%的升高幅度降低至约20%。SHBG水平与治疗反应之间无关联。